Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962307 | 0.85 | SIGMAR1 (0.45) | CYP3A4TDP1TRPA1ALDH1A1TSHR | |
| SCHEMBL119714 | 0.84 | CYP4F2 (0.42) | GRM2PPARGPPARATRPA1ALDH1A1 | |
| SCHEMBL29357072 | 0.84 | CYP4F2 (0.42) | GRM2PPARGPPARATRPA1ALDH1A1 | |
| SCHEMBL7004001 | 0.81 | CYP3A4 (0.39) | CYP3A4TDP1TRPA1ALDH1A1TSHR | |
| SCHEMBL3534570 | 0.79 | CYP1A2 (0.42) | CYP3A4TDP1TRPA1ALDH1A1TSHR | |
| SCHEMBL1503288 | 0.75 | ALDH1A1 (0.50) | CYP3A4TDP1TRPA1ALDH1A1TSHR | |
| SCHEMBL5972931 | 0.75 | TRPA1 (0.45) | CYP3A4TDP1TRPA1ALDH1A1TSHR | |
| SCHEMBL30705746 | 0.74 | TRPA1 (0.59) | CYP3A4TDP1TRPA1ALDH1A1TSHR | |
| SCHEMBL5972755 | 0.74 | TDP1 (0.46) | CYP3A4TDP1TRPA1ALDH1A1TSHR | |
| SCHEMBL19678032 | 0.73 | ALDH1A1 (0.52) | CYP3A4TDP1TRPA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208016-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-05 | — | — | US | disclosed |
| US-6972299-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMANN-LA ROCHE INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-6927232-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMAN-LA ROCHE INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1349839-B8 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1349839-B1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6706707-B2 | TREATMENT OR PREVENTION OF MGLUR5 RECEPTOR MEDIATED DISORDERS. | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-11-06 | — | — | US | disclosed |
| EP-1349839-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | F.HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002046166-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM6 | GRM2 6/4885CYP3A4 1589/4885TDP1 3415/4885 |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | GIPR, PROKR1, PROKR2 | GRM2 173/4885CYP3A4 4191/4885TDP1 4758/4885 |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | GRM2 5/4885CYP3A4 1634/4885TDP1 3819/4885 |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | GRM2 5/4885CYP3A4 1634/4885TDP1 3819/4885 |
| US-10208016-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | GIPR, PROKR1, PROKR2 | GRM2 173/4885CYP3A4 4191/4885TDP1 4758/4885 |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, HRH4 | GRM2 5/4885CYP3A4 1418/4885TDP1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.